Loading, Please Wait...
MENLO PARK, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, is hosting its Annual Shareholder Meeting and Investor Update on June 18, 2019.
Annual Shareholder Meeting Information:
Date: June 18, 2019
Time: 10:30 a.m. (Pacific Time)
Live Webcast: www.virtualshareholdermeeting.com/COB19
On the same day, CohBar will also provide a company update for investors via conference call and accompanying slide presentation.
Investor Update and Slide Presentation Information:
Date: June 18, 2019
Time: 2:00 p.m. (Pacific Time)
For individuals participating in the Investor Update Call and Slide Presentation, please call into the conference audio and log into Webex approximately 10 minutes prior to its start.
An audio recording of the call will be available beginning at 5:00 p.m. (Pacific Time) on June 18, 2019, through July 9, 2019. To access the recording please dial 1-844-512-2921 in the U.S. and Canada, or 1-412-317-6671 internationally, and reference Conference ID No. 3593731. The audio recording along with the slide presentation will also be available at www.cohbar.com during the same period.
CohBar’s lead program is based on CB4211, a first-in-class mitochondria based therapeutic that has demonstrated significant therapeutic potential in preclinical models of nonalcoholic steatohepatitis (NASH) and obesity. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial-derived peptide which was discovered in 2012 by CohBar founder Dr. Pinchas Cohen and his academic collaborators and has been shown to play a significant role in the regulation of metabolism. In July 2018, CB4211 entered a Phase 1a/1b clinical trial which includes an activity evaluation relevant to NASH and obesity. In November 2018, the company announced the temporary suspension of the trial to address mild but persistent injection site reactions, and announced the anticipated resumption of the clinical trial in May 2019. NASH has been estimated to affect as many as 12% of adults in the U.S., and there is currently no approved treatment for the disease.
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring peptides within the mitochondrial genome which regulate metabolism, cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides into mitochondria based therapeutics that offer the potential to address a broad range of age-related diseases, including nonalcoholic steatohepatitis (NASH), obesity, type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs.
For additional company information, please visit www.cohbar.com.
This news release contains forward-looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include CohBar’s plans and expectations for its lead candidate program, including anticipated timing and results of IND-enabling activities and clinical trials; statements regarding the therapeutic potential of these and other mitochondria based therapeutics, and the potential for additional discoveries, and our plans and expectations regarding intellectual property protection and potential financing activities. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. These risks and uncertainties include: the ability of the company to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials and the possibility that the resumption of the Phase 1 clinical trial will be delayed or that the Phase 1 clinical trial may not resume at all, the ability of the company to meet anticipated key dates for studies, the possibility of unfavorable study results, such as unfavorable new data and additional analyses of existing data, results that are different from earlier data results including less favorable than and that may not support further clinical development; the ability of the company to gain sufficient funds and support from corporate partnerships; its ability to raise sufficient funds from investors; the ability of the company’s intellectual property rights to protect product positions; and the ability of the company to retain key personnel and expand its research operations. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.
Investor and Media Contact:
Jeff Biunno, CFO